-

Epineuron Receives FDA 510(k) Clearance for Evala® Nerve Stimulator

Evolution in intraoperative nerve identification and evaluation.

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Epineuron, a medical device company pioneering bioelectronic medicine, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Evala® Nerve Stimulator. This handheld, intraoperative electrical stimulation device is engineered to provide surgeons with a rapid and accurate solution for nerve identification and functional evaluation of different nerve sizes, large and small. This milestone marks a significant expansion of the company’s portfolio and commercial footprint of its proprietary bioelectronic platform for peripheral nerve care.

"I am impressed with the versatility of the product allowing me to evaluate nerves in scarred revision surgeries, nerve transfers, under extended tourniquet time…" Dr. Dengler

Share

Dr. Jana Dengler, MD, MASc, MHSc, a peripheral nerve surgeon at the renowned Sunnybrook Health Sciences Centre in Toronto, ON, was among the early users of Evala®. “I am impressed with the versatility of the product allowing me to evaluate nerves in scarred revision surgeries, nerve transfers, under extended tourniquet time, and in conjunction with PeriPulse,” said Dr. Dengler.

"At Epineuron, we’ve listened closely to surgeons that expressed a significant need for more than just nerve stimulation hardware, they needed a cohesive ecosystem for nerve care," said Sergio Aguirre, CEO. "We’ve broadened our technology by complementing PeriPulse® with Evala® to support surgeons during the most demanding aspects of a procedure. Whether it’s protecting nerves in real-time or boosting their regenerative capacity afterward, our technology integrates seamlessly into the surgical workflow to enhance efficiency and offer patients the best path to recovery. "

The expansion of Epineuron’s portfolio reflects its dedication to delivering transformative bioelectronic advancements to the field of peripheral nerve care, highlighting the company’s enduring promise to clinicians and the patients they serve.

For more information, visit www.epineurontech.com.

About Epineuron

Epineuron Technologies Inc. is a commercial-stage medical device company dedicated to restoring function through our proprietary bioelectronic solutions for nerve evaluation and regeneration. Headquartered in Mississauga, ON, our mission is to empower clinicians and improve patient quality of life by providing simple, intuitive, and effective bioelectronic solutions that streamline decision-making and unlock the therapeutic potential of the peripheral nervous system.

Contacts

Dr. Mike Willand, PhD, PEng
info@epineurontech.com

Epineuron Technologies Inc.


Release Summary
Epineuron announces FDA clearance of Evala®, a next-generation nerve stimulator for nerve evaluation
Release Versions

Contacts

Dr. Mike Willand, PhD, PEng
info@epineurontech.com

Social Media Profiles
More News From Epineuron Technologies Inc.

Epineuron Announces Health Canada Approval of the PeriPulse™ System for Nerve Regeneration

TORONTO--(BUSINESS WIRE)--Epineuron receives Health Canada approval for its flagship product, the PeriPulse™ Nerve Stimulation System....

Epineuron Announces Enrollment of its First Patient in REGAIN™

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Epineuron jumpstarts REGAIN™, a pivotal trial evaluating its bioelectronic device to treat nerve damage, with the enrollment of its first patient....
Back to Newsroom